FDA
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, N
-
-
-
-
-
-
-
Black Diamond Therapeutics (BDTX) Announces CEO Transition
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Black Diamond Therapeutics (BDTX) Presents Preclinical Data on BDTX-1535 and BDTX-4933
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

